Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Cancer-associated thrombosis: limitations of conventional models and advances with endothelial cell-based microfluidics incorporating thrombin generation
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Authors
Apart from cancer progression itself, cancer-associated thrombosis (CAT) is the second leading cause of death among cancer patients. However, the mechanisms underlying CAT remain incompletely understood. Traditional animal models cannot fully reproduce the complex pathophysiological process of CAT in humans. Meanwhile, existing clinical prediction models are still insufficient to provide reliable risk prediction tools for venous thromboembolism (VTE) in cancer patients. With the accelerating development of microfluidics technology, it has become possible to construct thrombotic microenvironments with high physiological relevance in vitro, providing a new platform for the study of CAT. In this review, we summarized the contributions and limitations of animal models and clinical studies to CAT, and highlighted a series of artificial vascular microfluidics developed by our research group in recent years that can, to some extent, simulate the in vivo microenvironment for CAT. Based on this microfluidics platform, we conducted thrombin generation analysis to explore the potential mechanisms of cancer-related thrombosis and predict VTE risk in cancer patients. Finally, we further discuss the key issues and the challenges in the future.
Graphical Abstract
Downloads
Download data is not yet available.
Citations
1. Li A, La J, May SB, et al. Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems. J Clin Oncol 2023;41:2926-38. DOI: https://doi.org/10.1200/JCO.22.01542
2. Khorana AA, Dalal MR, Lin J, Connolly GC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res 2013;5:101-8. DOI: https://doi.org/10.2147/CEOR.S39964
3. Abdol Razak NB, Jones G, Bhandari M, et al. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 2018;10:380. DOI: https://doi.org/10.3390/cancers10100380
4. Verso M, Moik F, Graziani M, Cohen AT. Targeted anti-cancer agents and risk of venous thromboembolism. Haematologica 2024;109:3868-78. DOI: https://doi.org/10.3324/haematol.2023.284778
5. Roopkumar J, Swaidani S, Kim AS, et al. Increased incidence of venous thromboembolism with cancer immunotherapy. Med (N Y) 2021;2:423-34. DOI: https://doi.org/10.1016/j.medj.2021.02.002
6. Arteaga AJM, Font C, Rojas Hernandez CM. Quality of life in oncological patients with venous thromboembolic disease. Res Pract Thromb Haemost 2024;8:102510. DOI: https://doi.org/10.1016/j.rpth.2024.102510
7. Jee J, Brannon AR, Singh R, et al. DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism. Nat Med 2024;30:2499-507. DOI: https://doi.org/10.1038/s41591-024-03195-0
8. Hisada Y, Mackman N. Mouse models of cancer-associated thrombosis. Thromb Res 2018;164:S48-53. DOI: https://doi.org/10.1016/j.thromres.2017.12.018
9. Jiang F, Zhang Y, Ju LA. A microfluidic approach for early prediction of thrombosis in patients with cancer. Cell Rep Methods 2023;3:100536. DOI: https://doi.org/10.1016/j.crmeth.2023.100536
10. Kobayashi M, Wada H, Fukui S, et al. A clot waveform analysis showing a hypercoagulable state in patients with malignant neoplasms. J Clin Med 2021;10:5352. DOI: https://doi.org/10.3390/jcm10225352
11. Tsantes AG, Petrou E, Tsante KA, et al. Cancer-associated thrombosis: pathophysiology, laboratory assessment, and current guidelines. Cancers (Basel) 2024;16:2082. DOI: https://doi.org/10.3390/cancers16112082
12. Kapteijn MY, Yanovska M, Laghmani EH, et al. Modeling cancer-associated hypercoagulability using glioblastoma spheroids in microfluidic chips. Res Pract Thromb Haemost 2024;8:102475. DOI: https://doi.org/10.1016/j.rpth.2024.102475
13. Rondon AMR, Featherby S, Gomes T, et al. Comparison of the procoagulant activity between extracellular vesicles obtained from cellular monolayers and spheroids. J Thromb Thrombolysis 2025;58:458-66. DOI: https://doi.org/10.1007/s11239-025-03076-4
14. Buijs JT, van Beijnum R, Anijs RJS, et al. The association of tumor-expressed REG4, SPINK4 and alpha-1 antitrypsin with cancer-associated thrombosis in colorectal cancer. J Thromb Thrombolysis 2024;57:370-80. DOI: https://doi.org/10.1007/s11239-023-02907-6
15. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012;209:819-35. DOI: https://doi.org/10.1084/jem.20112322
16. Hisada Y, Ay C, Auriemma AC, et al. Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size. J Thromb Haemost 2017;15:2208-17. DOI: https://doi.org/10.1111/jth.13809
17. Thomas GM, Panicot-Dubois L, Lacroix R, et al. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009;206:1913-27. DOI: https://doi.org/10.1084/jem.20082297
18. Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008;6:1517-24. DOI: https://doi.org/10.1111/j.1538-7836.2008.02987.x
19. Kobayashi S, Koizume S, Takahashi T, et al. Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Cancer Sci 2021;112:4679-91. DOI: https://doi.org/10.1111/cas.15106
20. van Es N, Hisada Y, Di Nisio M, et al. Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: a prospective cohort study. Thromb Res 2018;166:54-9. DOI: https://doi.org/10.1016/j.thromres.2018.04.009
21. Shirai T, Tsukiji N, Sasaki T, et al. Cancer-associated fibroblasts promote venous thrombosis through podoplanin/CLEC-2 interaction in podoplanin-negative lung cancer mouse model. J Thromb Haemost 2023;21:3153-65. DOI: https://doi.org/10.1016/j.jtha.2023.07.005
22. Sasano T, Gonzalez-Delgado R, Munoz NM, et al. Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. J Thromb Haemost 2022;20:104-14. DOI: https://doi.org/10.1111/jth.15544
23. Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood 2019;134:1912-8. DOI: https://doi.org/10.1182/blood.2019001388
24. Burdett KB, Unruh D, Drumm M, et al. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood 2023;141:1322-36. DOI: https://doi.org/10.1182/blood.2022017858
25. Lucotti S, Ogitani Y, Kenific CM, et al. Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell 2025;188:1642-61. DOI: https://doi.org/10.1016/j.cell.2025.01.025
26. Li N, Yin C, Tao J. Neutrophil extracellular traps in tumor metastasis: mechanisms and therapeutic implications. Discov Oncol 2025;16:1631. DOI: https://doi.org/10.1007/s12672-025-03451-w
27. Leal AC, Mizurini DM, Gomes T, et al. Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci Rep 2017;7:6438. DOI: https://doi.org/10.1038/s41598-017-06893-7
28. Pabinger I, Posch F. Flamethrowers: blood cells and cancer thrombosis risk. Hematology Am Soc Hematol Educ Program 2014;2014:410-7. DOI: https://doi.org/10.1182/asheducation-2014.1.410
29. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-5. DOI: https://doi.org/10.1126/science.1092385
30. Zhou Y, Tao W, Shen F, et al. The emerging role of neutrophil extracellular traps in arterial, venous and cancer-associated thrombosis. Front Cardiovasc Med 2021;8:786387. DOI: https://doi.org/10.3389/fcvm.2021.786387
31. Nakazawa D, Tomaru U, Yamamoto C, et al. Abundant neutrophil extracellular traps in thrombus of patient with microscopic polyangiitis. Front Immunol 2012;3:333. DOI: https://doi.org/10.3389/fimmu.2012.00333
32. Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 2014;40:277-83. DOI: https://doi.org/10.1055/s-0034-1370765
33. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010;16:887-96. DOI: https://doi.org/10.1038/nm.2184
34. Plantureux L, Mege D, Crescence L, et al. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis. Cancers (Basel) 2018;10:441. DOI: https://doi.org/10.3390/cancers10110441
35. Unlu B, Heestermans M, Laghmani EH, et al. The effects of an aggressive breast tumor on thrombosis after antithrombin downregulation in a hypercoagulable mouse model. Thromb Res 2024;244:109200. DOI: https://doi.org/10.1016/j.thromres.2024.109200
36. Liu Z, Wang J, Liao F, et al. Tumor-educated platelets facilitate thrombus formation through migration. Front Oncol 2022;12:857865. DOI: https://doi.org/10.3389/fonc.2022.857865
37. Bekendam RH, Ravid K. Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms. Front Cell Dev Biol 2023;11:1207395. DOI: https://doi.org/10.3389/fcell.2023.1207395
38. Palacios-Acedo AL, Mezouar S, Mege D, et al. P2RY12-inhibitors reduce cancer-associated thrombosis and tumor growth in pancreatic cancers. Front Oncol 2021;11:704945. DOI: https://doi.org/10.3389/fonc.2021.704945
39. Wrobleski SK, Farris DM, Diaz JA, et al. Mouse complete stasis model of inferior vena cava thrombosis. J Vis Exp 2011;52:e2738. DOI: https://doi.org/10.3791/2738
40. Tadokoro H, Ota Y, Uomoto M, et al. A mouse model of deep vein thrombosis by inferior vena cava hypoperfusion using ameroid constrictors. Sci Rep 2025;15:928. DOI: https://doi.org/10.1038/s41598-024-84443-8
41. Brill A, Fuchs TA, Chauhan AK, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011;117:1400-7. DOI: https://doi.org/10.1182/blood-2010-05-287623
42. Diaz JA, Obi AT, Myers DD Jr, et al. Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol 2012;32:556-62. DOI: https://doi.org/10.1161/ATVBAHA.111.244608
43. Jirouskova M, Shet AS, Johnson GJ. A guide to murine platelet structure, function, assays, and genetic alterations. J Thromb Haemost 2007;5:661-9. DOI: https://doi.org/10.1111/j.1538-7836.2007.02407.x
44. Sambrano GR, Weiss EJ, Zheng YW, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001;413:74-8. DOI: https://doi.org/10.1038/35092573
45. Renna SA, Michael JV, Kong X, et al. Human and mouse PAR4 are functionally distinct receptors: studies in novel humanized mice. J Thromb Haemost 2022;20:1236-47. DOI: https://doi.org/10.1111/jth.15669
46. Rowley JW, Oler AJ, Tolley ND, et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011;118:e101-11. DOI: https://doi.org/10.1182/blood-2011-03-339705
47. Wolberg AS. Mice, men, and differences therein. J Thromb Haemost 2019;17:1440-2. DOI: https://doi.org/10.1111/jth.14572
48. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005;129:307-21. DOI: https://doi.org/10.1111/j.1365-2141.2005.05444.x
49. Marques IS, Almeida R, Costa PF. Organ-on-chip technologies at the cancer-thrombosis interface. Trends Biotechnol 2025;43:online ahead of print. DOI: https://doi.org/10.1016/j.tibtech.2025.10.001
50. Depasse F, Binder NB, Mueller J, et al. Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine. J Thromb Haemost 2021;19:2907-17. DOI: https://doi.org/10.1111/jth.15529
51. Al-Amer OM. The role of thrombin in haemostasis. Blood Coagul Fibrinolysis 2022;33:145-8. DOI: https://doi.org/10.1097/MBC.0000000000001130
52. Unlu B, van Es N, Arindrarto W, et al. Genes associated with venous thromboembolism in colorectal cancer patients. J Thromb Haemost 2018;16:293-302. DOI: https://doi.org/10.1111/jth.13926
53. Anijs RJS, Nguyen YN, Yanovska M, et al. Regenerating islet-derived family member 4 (REG4) does not influence parameters of hemostasis in colorectal cancer. Thromb Res 2025;256:109535. DOI: https://doi.org/10.1016/j.thromres.2025.109535
54. Rosati G, Aprile G, Colombo A, et al. Colorectal cancer heterogeneity and the impact on precision medicine and therapy efficacy. Biomedicines 2022;10:1035. DOI: https://doi.org/10.3390/biomedicines10051035
55. Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I17-21. DOI: https://doi.org/10.1161/01.CIR.0000078466.72504.AC
56. van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 2017;102:1494-501. DOI: https://doi.org/10.3324/haematol.2017.169060
57. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377-82. DOI: https://doi.org/10.1182/blood-2010-02-270116
58. Cella CA, Di Minno G, Carlomagno C, et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist 2017;22:601-8. DOI: https://doi.org/10.1634/theoncologist.2016-0246
59. Yan AR, Yip D, Peterson GM, et al. External validation of risk scores for predicting venous thromboembolism in ambulatory patients with lung cancer. Cancers (Basel) 2024;16:3165. DOI: https://doi.org/10.3390/cancers16183165
60. Pelzer U, Sinn M, Stieler J, Riess H. Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? Dtsch Med Wochenschr 2013;138:2084-8. DOI: https://doi.org/10.1055/s-0033-1349608
61. Spyropoulos AC, Eldredge JB, Anand LN, et al. External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: the COMPASS-CAT venous thromboembolism risk assessment model. Oncologist 2020;25:e1083-90. DOI: https://doi.org/10.1634/theoncologist.2019-0482
62. Cella CA, Knoedler M, Hall M, et al. Validation of the ONKOTEV risk prediction model for venous thromboembolism in outpatients with cancer. JAMA Netw Open 2023;6:e230010. DOI: https://doi.org/10.1001/jamanetworkopen.2023.0010
63. Munoz Martin AJ, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer 2018;118:1056-61. DOI: https://doi.org/10.1038/s41416-018-0027-8
64. Zhang L, Fang Y, Xing J, et al. The efficacy of the systemic immune-inflammation index and prognostic nutritional index for the diagnosis of venous thromboembolism in gastrointestinal cancers. J Inflamm Res 2022;15:4649-61. DOI: https://doi.org/10.2147/JIR.S376601
65. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7. DOI: https://doi.org/10.1182/blood-2007-10-116327
66. Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the PROTECHT score. Intern Emerg Med 2012;7:291-2. DOI: https://doi.org/10.1007/s11739-012-0784-y
67. Alexander M, Ball D, Solomon B, et al. Dynamic thromboembolic risk modelling to target appropriate preventative strategies for patients with non-small cell lung cancer. Cancers (Basel) 2019;11:50. DOI: https://doi.org/10.3390/cancers11010050
68. Antic D, Milic N, Nikolovski S, et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol 2016;91:1014-9. DOI: https://doi.org/10.1002/ajh.24466
69. Rupa-Matysek J, Brzezniakiewicz-Janus K, Gil L, et al. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Med 2018;7:2868-75. DOI: https://doi.org/10.1002/cam4.1540
70. Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A predictive score for thrombosis associated with breast, colorectal, lung or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist 2017;22:1222-31. DOI: https://doi.org/10.1634/theoncologist.2016-0414
71. Pabinger I, van Es N, Heinze G, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018;5:e289-98. DOI: https://doi.org/10.1016/S2352-3026(18)30063-2
72. Castellon Rubio VE, Segura PP, Munoz A, et al. High plasma levels of soluble P-selectin and factor VIII predict venous thromboembolism in non-small cell lung cancer patients: the THROMBO-NSCLC risk score. Thromb Res 2020;196:349-54. DOI: https://doi.org/10.1016/j.thromres.2020.09.021
73. Li H, Tian Y, Niu H, et al. Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: a retrospective case-control study. Front Oncol 2022;12:988287. DOI: https://doi.org/10.3389/fonc.2022.988287
74. Gomez-Rosas P, Giaccherini C, Russo L, et al. A new risk prediction model for venous thromboembolism and death in ambulatory lung cancer patients. Cancers (Basel) 2023;15:4588. DOI: https://doi.org/10.3390/cancers15184588
75. Lopez Sacerio A, Tejeda Ramon MC, Morales Helguera A, et al. Validation of venous thromboembolism predictive model in hematologic malignancies. Ann Hematol 2023;102:3613-20. DOI: https://doi.org/10.1007/s00277-023-05463-4
76. Li B, Lu Z, Yang Z, et al. Monitoring circulating platelet activity to predict cancer-associated thrombosis. Cell Rep Methods 2023;3:100513. DOI: https://doi.org/10.1016/j.crmeth.2023.100513
77. Fan D, Lanting V, Camilleri E, et al. Coagulation parameters in gastrointestinal cancer patients with venous thromboembolism. Thromb Res 2026;258:109587. DOI: https://doi.org/10.1016/j.thromres.2026.109587
78. Chernysh IN, Nagaswami C, Kosolapova S, et al. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep 2020;10:5112. DOI: https://doi.org/10.1038/s41598-020-59526-x
79. Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Subcell Biochem 2017;82:405-56. DOI: https://doi.org/10.1007/978-3-319-49674-0_13
80. Di Cera E. Thrombin as procoagulant and anticoagulant. J Thromb Haemost 2007;5:196-202. DOI: https://doi.org/10.1111/j.1538-7836.2007.02485.x
81. Hao Z, Lv H, Tan R, et al. A three-dimensional microfluidic device for monitoring cancer and chemotherapy-associated platelet activation. ACS Omega 2021;6:3164-72. DOI: https://doi.org/10.1021/acsomega.0c05572
82. Karel MFA, Tullemans BME, D’Italia G, et al. The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions. Thromb Res 2022;212:72-80. DOI: https://doi.org/10.1016/j.thromres.2022.02.020
83. John A, Robador JR, Vidal YSS, et al. Urothelial carcinoma of the bladder induces endothelial cell activation and hypercoagulation. Mol Cancer Res 2020;18:1099-109. DOI: https://doi.org/10.1158/1541-7786.MCR-19-1041
84. Goerge T, Kleineruschkamp F, Barg A, et al. Microfluidics reveals generation of platelet-strings on tumor-activated endothelium. Thromb Haemost 2007;98:283-6. DOI: https://doi.org/10.1160/TH07-03-0163
85. Deng Y, Zhou Y, Tay HM, et al. Real-time imaging of platelet dynamics in engineered arterial, venous, and cancer-associated thrombotic microenvironments. Biofabrication 2026;18:015022. DOI: https://doi.org/10.1088/1758-5090/ae302c
86. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017;130:1499-506. DOI: https://doi.org/10.1182/blood-2017-03-743211
87. Anderson R, Rapoport BL, Steel HC, Theron AJ. Pro-tumorigenic and thrombotic activities of platelets in lung cancer. Int J Mol Sci 2023;24:11927. DOI: https://doi.org/10.3390/ijms241511927
88. Beckman JD, DaSilva A, Aronovich E, et al. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions. J Thromb Haemost 2023;21:1366-80. DOI: https://doi.org/10.1016/j.jtha.2023.01.027
89. Mauracher LM, Posch F, Martinod K, et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J Thromb Haemost 2018;16:508-18. DOI: https://doi.org/10.1111/jth.13951
90. Seo JD, Gu JY, Jung HS, et al. Contact system activation and neutrophil extracellular trap markers: risk factors for portal vein thrombosis in patients with hepatocellular carcinoma. Clin Appl Thromb Hemost 2019;25:1076029618825310. DOI: https://doi.org/10.1177/1076029618825310
91. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007;100:174-90. DOI: https://doi.org/10.1161/01.RES.0000255690.03436.ae
92. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004;104:2752-60. DOI: https://doi.org/10.1182/blood-2004-04-1396
93. Whitworth CP, Polacheck WJ. Vascular organs-on-chip made with patient-derived endothelial cells: technologies to transform drug discovery and disease modeling. Expert Opin Drug Discov 2024;19:339-51. DOI: https://doi.org/10.1080/17460441.2023.2294947
94. Manz XD, Albers HJ, Symersky P, et al. In vitro microfluidic disease model to study whole blood-endothelial interactions and blood clot dynamics in real-time. J Vis Exp 2020;159:e61068. DOI: https://doi.org/10.3791/61068-v
95. Lewis DM, Abaci HE, Xu Y, Gerecht S. Endothelial progenitor cell recruitment in a microfluidic vascular model. Biofabrication 2015;7:045010. DOI: https://doi.org/10.1088/1758-5090/7/4/045010
96. Weener HJ, van Haaps TF, van Helden RWJ, et al. Blood-perfused vessels-on-chips stimulated with patient plasma recapitulate endothelial activation and microthrombosis in COVID-19. Lab Chip 2025;25:1787-800. DOI: https://doi.org/10.1039/D4LC00848K
Supporting Agencies
China Scholarship CouncilHow to Cite
1.
Fan D, Rondon AM, Versteeg HH. Cancer-associated thrombosis: limitations of conventional models and advances with endothelial cell-based microfluidics incorporating thrombin generation. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/438
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
